Although immune checkpoint blockade (ICB) therapies, such as PD-L1 inhibition, have been identified as effective treatment strategies for various cancers, their efficacy as monotherapies in COAD is limited due to the dynamic and immunosuppressive nature of the tumor microenvironment (Passardi et al., 2017). The gene discussed is CD274; the disease is cancer.